抽象的な
Bortezomib in the initial treatment of inducing chemotherapy of multiple myeloma and autologous stem cell transplantation pre-treatment
Gang Zhang, Lin-Lin Yang, Jing Yu, Qi-Yu Sheng, Li Li
Objective: This study investigates the effects of bortezomib on the initial treatment of inducing chemotherapy of multiple myeloma and autologous stem cell transplantation pre-treatment.
Methods: Eight cases of patients with multiple myeloma were treated with BDT chemotherapy regimen for four cycles (bortezomib 1.3 mg/m2 d 1, d 4, d 8, d 11, dexamethasone, 20 mg, d 1-4, d 9-12; 100-200 mg thalidomide for long term). Eight cases of patients with autologous peripheral blood stem cell transplantation pre-treatment were performed using bortezomib+Melphalan (bortezomib 1.0 mg/m2, -6 d, -3 d, +1 d +4 d; Melphalan 200 mg/m2, -2 d). The mobilization regimen was cyclophosphamide +bortezomib+dexamethasone+G-CSF5~10 μg/(kg/d-1).
Results: The partial or complete remission occurred in the eight cases of patients with multiple myeloma after BDT chemotherapy for four cycles. Stem cell collection was successful. Meanwhile, the hematopoietic functions of patients with autologous stem cell transplantation were successfully reconstructed.
Conclusion: The bortezomib combined with autologous stem cell transplantation is an effective method for the treatment of multiple myeloma. It is safe and reliable. Moreover, the maintenance therapy of bortezomib after transplantation may prolong the survival time of patients and improve the quality of life.